RNA interference-mediated secretory clusterin gene silencing inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cells

Author(s): Yan Y, Luo K, Zhang H, Chai W

Abstract

Background/aims: Non-small cell lung cancer (NSCLC) constitutes around 85% of lung cancer cases and is frequently beyond surgical intervention.

Methodology: Secretory clusterin (sCLU) is found in diverse types of human cancers and is unregulated in a variety of cell lines in response to stress, and enhances cancer cell survival. However, the roles of sCLU in NSCLC are still to be elucidated.

Results: Here we show that RNA interference (RNAi)-mediated sCLU gene silencing with short interference RNA (siRNA) strongly decreased the sCLU mRNA and protein levels, as well as suppressed cell proliferation and induced cell apoptosis. In addition, sCLU siRNA also blocked the PI3K/AKT signaling pathway, and decreased the AKT phosphorylation level, but no change was found in total AKT level. More importantly, PI3K/AKT signaling pathway inhibitor, LY294002, also reduced tumor cell proliferation, which is similar to the result with or without sCLU siRNA treatment.

Conclusions: These results suggest that sCLU plays a positive role in NSCLC cell proliferation, which may be mediated by the PI3K/AKT signaling pathway. Our work in this study demonstrates RNAi-mediated sCLU gene silencing may provide a novel therapeutic strategy in the treatment of NSCLC.

Similar Articles

Current management of small cell lung cancer

Author(s): Neal JW, Gubens MA, Wakelee HA

Mechanisms of resistance to cisplatin

Author(s): Kartalou M, Essigmann JM

Expression of clusterin in human pancreatic cancer

Author(s): Xie MJ, Motoo Y, Su SB, Mouri H, Ohtsubo K, et al.

Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer

Author(s): Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, et al.

Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells

Author(s): Cheng CY, Cherng SH, Wu WJ, Yang TY, Huang XY, et al.

Clusterin as a therapeutic target for radiation sensitization in a lung cancer model

Author(s): Cao C, Shinohara ET, Li H, Niermann KJ, Kim KW, et al.

Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway

Author(s): Bortul R, Tazzari PL, Billi AM, Tabellini G, Mantovani I, et al.

Modulation of PI3K/Akt pathway by E1a mediates sensitivity to cisplatin

Author(s): Guinea Viniegra J, Hernández Losa J, Sánchez-Arévalo VJ, ParadaCobo C, FernándezSoria VM, et al.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

Author(s): McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, et al.

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Author(s): McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, et al.

Raf kinase as a target for anticancer therapeutics

Author(s): Sridhar SS, Hedley D, Siu LL

Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair

Author(s): Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, et al.

Clusterin regulates drug-resistance in melanoma cells

Author(s): Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, et al.

The Raf/MEK/ERK pathway: new concepts of activation

Author(s): Peyssonnaux C, Eychène A